CHEK2P2

Across TCGA pan-cancer cohorts, CHEK2P2 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated CHEK2P2 data layer compared with 1 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CHEK2P2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CHEK2P2 expression acts as an unfavorable survival marker, although some lineages such as KIRC and KIRP show a favorable association.

LIHC, KIRC, and BRCA are the cancer types where CHEK2P2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.544	0.727	<.001	69	view →
KIRC	OS	Median	All	0.732	0.575	.002	65	view →
BRCA	DFS	Tertile	All	0.140	1.000	.001	54	view →
COAD	OS	Tertile	II,III,IV	0.671	0.866	.008	54	view →
UCEC	OS	Tertile	III,IV	0.729	0.870	.005	46	view →
PCPG	DFS	Tertile	All	0.641	0.912	<.001	42	view →
UCS	DFS	Median	IV	0.490	0.835	.031	30	view →
LGG	DFS	Tertile	All	0.218	0.465	.001	21	view →
KIRP	DFS	Tertile	III,IV	0.801	0.189	.005	20	view →
PRAD	DFS	Tertile	All	0.921	0.737	.026	18	view →
ESCA	DFS	Quartile	All	0.369	0.572	.010	15	view →
KICH	OS	Quartile	III,IV	0.650	0.947	.034	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

CHEK2P2–LIHC (OS)

Open the LIHC breakdown →